Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly study

Circulation

Volumn 112, Issue 20, 2005, Pages 3080-3087

  Smith, Ann ^a   Patterson, Chris ^a   Yarnell, John ^a   Rumley, Ann ^b   Ben Shlomo, Yoav ^c   Lowe, Gordon ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Coagulation; Coronary disease; Fibrinogen; Fibrinolysis; Stroke

Indexed keywords

FIBRINOGEN; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SEX RATIO;

EID: 30944441643     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.557132     Document Type: Article

References (41)

1. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost. 2001;85:584-595.
2. Lowe GDO, Rumley A, Whincup PH, Danesh J. Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med. 2002;2:429-440.
3. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
4. Danesh J, Collins R, Peto R, Lowe GDO. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J. 2000;21:515-520.
5. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001;103:2323-2327.
6. Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. Von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2002;23:1764-1770.
7. Lowe GDO, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH. Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2004;25:252-259.
8. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146:948-957.
9. Lowe GDO, Rumley A, Woodward M, Reid E, Rumley J. Activated protein C resistance and the FV: R506Q mutation in a random population sample: associations with cardiovascular risk factors and coagulation variables. Thromb Haemost. 1999;81:918-924.
10. Kiechl S, Muigg A, Santer P, Mitterer M, Egger G, Oberhollenzer M, Oberhollenzer F, Mayr A, Gasperi A, Poewe W, Willeit J. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation. 1999;99:614-619.
11. Zahn R, Beeck H, Winkelmann BR, Seidl K, Schneider S, Hellstem P, Senges J. Prospective cross-sectional study of haemostatic factors in patients with and without coronary heart disease. Blood Coagul Fibrinolysis. 2002;13:81-87.
12. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 1996;125:265-269.
13. Sweetnam PM, Thomas HF, Yarnell JW, Beswick AD, Baker IA, Elwood PC. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease: The Caerphilly and Speedwell studies. Eur Heart J. 1996;17: 1814-1820.
14. Sweetnam PM, Yarnell JW, Lowe GD, Baker IA, O'Brien JR, Rumley A, Etherington MD, Whitehead PJ, Elwood PC. The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: the Caerphilly and Speedwell studies. Br J Haematol 1998;100:582-588.
15. Rumley A, Lowe GDO, Sweetnam PM, Yarnell JWG, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Study. Br J Haematol. 1999;105:110-116.
16. Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost. 1998;79:129-133.
17. Lowe GDO, Rumley A, Sweetnam P, Yarnell JWG, Rumley J. Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost. 2001;86:822-827.
18. Baker IA, Pickering J, Elwood PC, Bayer A, Ebrahim S. Fibrinogen, viscosity and white blood cell count predict myocardial, but not cerebral infarction: evidence from the Caerphilly and Speedwell cohort. Thromb Haemost. 2002;87:421-425.
19. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stats Med. 1982;1:121-129.
20. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
21. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258:1183-1186.
22. Lowe GDO, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol. 1997;96:168-173.
23. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol. 1999;19:1368-1377.
24. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MF, Warlow CP. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke. 2004;35:2300-2305.
25. Fibrinogen Studies Collaboration. Collaborative meta-analysis of prospective observational studies of plasma fibrinogen and cardiovascular disease. Euro J Cardiovasc Prev Rehabil. 2003;11:9-17.
26. Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Haemostatic factors as predictors of ischaemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1997;17: 3321-3325.
27. Tait RC, Murdoch DL, O'Neill KF, McMahon A, Wallace IW, Rumley A, Jackson J, Lowe GDO. Fibrin D-dimer is an independent predictor of future stroke in patients with atrial fibrillation. Circulation. 2003; 108(suppl IV):IV-787. Abstract.
28. Fowkes FGR, Lowe GDO, Housley E, Fowkes FG, Lowe GD, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet. 1993;342:84-86.
29. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD. Comparison of novel haemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation. 2000;102:2816-2822.
30. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
31. Rosendaal FR, Briet E, Stibbe J, van Herpen G, Leuven JA, Hofman A, Vandenbroucke JP. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990;75:525-530.
32. Sramek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet. 2003;362:351-54.
33. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation. 1999;100:736-742.
34. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
35. Nilsson TK, Jansson JH, Bowman K. t-PA-PAI-1 complex as a risk factor for the development of a first stroke. Fibrinolysis. 1998;12(suppl 1):21. Abstract.
36. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, Ebrahim S. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327:1267-1270.
37. Topol EJ, Lauer MS. The rudimentary phase of personalised medicine: coronary risk scores. Lancet. 2003;362:1776-1777.
38. Yarnell JWG, Sweetnam PM, Rumley A, Lowe GD. Lifestyle and hemostatic risk for ischemic heart disease: the Caerphilly study. Arterioscler Thromb Vasc Biol. 2000;20:271-279.
39. Yarnell JWG, Sweetnam PM, Rumley A, Lowe GDO. Lifestyle factors and coagulation activation markers: the Caerphilly study. Blood Coagul Fibrinolysis. 2001;12:721-728.
40. Mansfield MW, Heywood DM, Grant PJ. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:160-164.
41. Yarnell JWG, Patterson CC, Sweetnam PM, Lowe GDO. Haemostatic/ inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur Heart J. 2004;25:1049-1056.